Researchers have launched a Phase IIb clinical trial for a new treatment aimed at Tourette Syndrome (TS) in adults. The study, conducted by NeuroThera Labs at the Yale Child Study Center, will evaluate a proprietary cannabinoid-based drug called SCI-110. This innovative treatment combines dronabinol, a synthetic form of THC, with palmitoylethanolamide, aiming to reduce tics and related symptoms while minimizing side effects.

This trial is particularly important for adults living with TS, a condition that often presents with severe and persistent symptoms, significantly impacting daily life. The previous Phase IIa study showed promising results, with participants experiencing an average tic reduction of 21%. If successful, SCI-110 could offer a new, effective option for managing TS, which currently has limited treatment alternatives.

The Phase IIb trial is designed as a randomized, double-blind, placebo-controlled study, meaning participants will either receive the treatment or a placebo without knowing which one they have. The trial will assess changes in tic severity over 12 and 26 weeks, providing crucial data on the drug’s efficacy and safety. While these findings are encouraging, it’s important to remember that this research is still in the early stages, and further validation is needed before any conclusions can be drawn about the treatment’s long-term benefits.

For those interested in exploring cannabinoid treatments, it may be worth discussing with a healthcare provider, especially if you or someone you know is affected by Tourette Syndrome.

For more information, see the original announcement from GlobeNewswire.